Quantum Science Is Bolstering Production Capability by Expanding Into a 2nd Laboratory in Daresbury, Cheshire

The manufacturer of the groundbreaking INFIQ® quantum dot (QD) technology, Quantum Science, is bolstering its production capability by expanding into a second laboratory at its site in Daresbury, Cheshire.

Serving as a high-volume manufacturing facility, the new laboratory will feature specialist equipment including a highly precise automated reaction system, which will help Quantum Science upscale its production to serve millions of SWIR sensors each year.

The expansion follows a year of rapid development for Quantum Science that has seen it go from a small start-up to an established innovator in the QD industry operating in numerous international markets.

Quantum Science’s INFIQ® QDs are light-absorbing nanocrystals with significant applications for the sensing and imaging fields.

Existing technologies either cannot detect light in the short-wave infrared (SWIR) wavelength, or are prohibitively expensive, whereas INFIQ® QDs offer competitive performance at a mass-market price.

Widespread use of this technology will advance the semiconductor and electronics industries and unlock applications for sectors including medicine, defence, automation, and more.

Commenting on the expansion, Dr Hao Pang, CEO and Founder of Quantum Science, said: “Quantum Science has already demonstrated its technology and product leadership in the market, and now is the time for us to take the next step in our journey. This expansion into a second lab means we will not only be producing world leading QD technology, but we can also significantly upscale our operations to the point that our materials will be able to serve millions of SWIR quantum dot sensors worldwide.

“This growth will put Quantum Science in an unparalleled position to serve the current and rising global SWIR quantum dot device markets. It also highlights our commitment to our mission: providing the SWIR industry with the best quantum dot materials and technologies, enabling developers to bring high-performance and affordable SWIR sensing and imaging to life.”

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.